Company Overview
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +147.01% |
| 6 Months: | +47.22% |
| 3 Months: | +26.17% |
| 1 Month: | -1.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMVT Immunovant, Inc. R2KR3KPHARMA | 39.25 | -13.97 | $8.11B | 0.00% | - | -80.10% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Jul 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 113.83M | 127.22M | 131.76M | 114.36M | 159.55M | - |
| Operating Income | - | - | - | - | - | -92.34K | -419.76K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -113.83M | -127.22M | -131.76M | -114.36M | -159.55M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -113.72M | -127.12M | -131.66M | -114.26M | -159.46M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.87M | -119.70M | -125.91M | -109.08M | -150.70M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 583.00K | 913.00K | 594.00K | 1.55M | -2.84M | - |
| Net Income | -4.37M | -4.37M | -6.35M | -8.85M | -450 | -20.06M | -14.48M | -11.30M | -26.71M | -20.79M | -31.78M | -30.47M | -37.70M | -41.38M | -40.37M | -47.93M | -63.23M | -73.94M | -58.66M | -51.42M | -87.15M | -109.12M | - | -106.45M | -120.61M | -126.50M | -110.64M | -147.86M | -153.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.38 | -0.25 | -0.32 | -0.31 | -0.35 | -0.36 | -0.35 | -0.41 | -0.49 | -0.57 | -0.45 | -0.36 | -0.60 | -0.74 | - | -0.64 | -0.71 | -0.73 | -0.61 | -0.73 | -0.75 |
| R&D Expense | - | - | - | 7.68M | - | 18.48M | 10.33M | 4.95M | 16.92M | 11.98M | 21.09M | 18.70M | 21.36M | 29.76M | 28.43M | 37.74M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -28.60M | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -505.61M |
| Diluted EPS | - | - | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 |
| R&D Expense | 25.73M | 47.93M | 68.60M | 101.81M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2018 | Jul 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.83M | 109.39M | 412.49M | 515.56M | 405.84M | 666.37M | 776.22M | 957.01M |
| Total Equity | -1.50M | -411.00K | 7.34M | 94.07M | 391.48M | 469.82M | 362.49M | 617.76M | 707.45M | 852.59M |
| Cash & Equivalents | - | - | 6.99M | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
| Total Liabilities | - | - | 6.49M | 15.32M | 21.01M | 45.74M | 43.34M | 48.61M | 68.78M | 104.42M |
| Current Liabilities | - | - | - | 15.32M | 18.77M | 44.52M | 43.30M | 48.61M | 68.78M | 104.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -28.55M | -53.36M | -83.33M | - | -188.19M | -214.23M | -375.87M | -407.31M |
| Investing Cash Flow | -52.00K | -31.00K | -210.00K | - | -197.00K | -360.00K | -759.00K | -8.00K |
| Financing Cash Flow | 35.58M | 146.97M | 383.11M | - | 70.89M | 472.43M | 454.49M | 595.76M |
| Capital Expenditure | -52.00K | -31.00K | -210.00K | - | -197.00K | -360.00K | -759.00K | -8.00K |
| Free Cash Flow | -28.60M | -53.39M | -83.54M | - | -188.39M | -214.59M | -376.63M | -407.32M |
| Net Change in Cash | - | - | - | - | -117.50M | 257.84M | 77.86M | 188.44M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | -389.7% | -70.6% | -27.4% | -33.4% | -58.2% | -42.0% | -58.5% | -59.3% |
| ROCE % | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 7.84% | 16.19M | $666.88M |
| 2 | Deep Track Capital, Lp | 4.52% | 9.34M | $384.86M |
| 3 | Blackrock Inc. | 3.48% | 7.18M | $295.85M |
| 4 | Farallon Capital Management LLC | 2.81% | 5.80M | $239.17M |
| 5 | Baker Bros. Advisors, LP | 2.63% | 5.44M | $223.93M |
| 6 | State Street Corporation | 2.24% | 4.62M | $190.22M |
| 7 | Morgan Stanley | 2.20% | 4.53M | $186.84M |
| 8 | TCG Crossover Management, LLC | 2.16% | 4.46M | $183.67M |
| 9 | Vanguard Portfolio Management LLC | 1.89% | 3.91M | $161.11M |
| 10 | Vanguard Capital Management LLC | 1.76% | 3.64M | $149.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMVT
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed | IMVT Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQN2lBM1U4dVppRXh4VXRMa2QxUTFGT1F0aWpiWXlJY1I0aEZrYTFJVXpDRmhGVzFUTmxPNFF2NVBobkdIYkh0ZjFuSUJGTzJrZjNsOUhjQmxfSFJ2RWtfODd5V1FqQ1p2REk3LU0zRFZBc2dKSS1HeHIwVzlvbDBYb0FzMUxtNUNhOXE1UG…
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNbWFtRHZpVGZiSFc4OUN2amltaUNmNU5uMjVYVTEwYzhvbFB4T1N2M0VBaWFtREtQY1F0S0R3OXNqdWxCY21EQUpkOFprbjRwZzhxR0htR2o0YUFLUFlDd1BrdmYtVnNuZUVkWGVsSmFFVU1RUy1FTXVlbmhEQUctWjg3RktOd0ZKd0pWQW…
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQdU5iU2pCem5kM0RYcDlFblUwV1Z5Ql9QLUFmcU9tZkFQMjlMSkp2UVV5amJVQk1xeGFrVlFwNmZVa2pIWEhWTWtZekpFZnFqUXZKWDFvbXpvM1RGWm9Oc0dPSTlTUlI1N2I1aEMycTdZLW1HT0tEOWE3Z2NiaktxM0lucnBaRV9rUFVwQj…
IMVT - Immunovant Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE41MFhDbC13dkFVSzdIbHB1RDdXNEZGTHVrRDBkc2VycWxLY1M0ZUtnV1UtQlluSGF0MFNKNE9xTHBURk9tUGc?oc=5" target="_blank">IMVT - Immunovant Inc Stock Price and Quote</a> <font color="…
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPNkZRbmN3SzB2QlpsWGphNkZMYTFVZG85S093OVNUX0FMZTZYUGxIS25RLW1zS2ZUbDZnWDlMVHJENzBwbmlxZ3pnQkRZWlJ1NFA2TXN2c2hBaGczUE1vNnlYM0U3YjAyYmlxbDBzOE1zR1l4MFlaQnpYVjJfQW5xbkdBdUVrVVFGbVo4dF…
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNeWpwV2RSX2VfWGQ3d0xYOTZiTjF2WGs4b1k2ZjM2dkdWaGxsaXN3MDlLVTdwRjZydDBtbU4yeWFDUnhWOEZ2OUZqeXpDeTdXZWcyaE5CVlVKMHo2OTI3eHZRN2ZBdXVsQjdvLXh6WUs3enlEaE92aUVxY0dpdm03am96X1BaZ19RWXJXY1…
IMVT — Frequently Asked Questions
What is the current share price of Immunovant, Inc. (IMVT)?
As of 2026-09-07 16:24 PDT, Immunovant, Inc. (IMVT) trades at $39.25 on NasdaqGS. Its 52-week range is $14.69 to $44.96.
What is the market capitalisation of IMVT?
Immunovant, Inc. (IMVT) has a market capitalisation of $8.11B on NasdaqGS.
What is the P/E ratio of IMVT?
IMVT trades at a trailing price-to-earnings (P/E) ratio of -13.97. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 9.56.
What is the return on equity (ROE) of IMVT?
IMVT has a return on equity (ROE) of -80.10%.
Is IMVT a good stock to buy?
This page provides a data-driven analysis of Immunovant, Inc. (IMVT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.